BioAdvance provides funding to startup life sciences companies in Southeastern Pennsylvania through its new $50 million Greenhouse Fund. They invest in therapeutics, devices, diagnostics and platform technologies focused on human health. Since its first investments in 2003, BioAdvance has become one of the nation's leading investors providing pre-seed and seed-stage funding. To date they have committed more than $40 million to more than 50 seed-stage companies and 17 pre-seed companies. Their portfolio companies are working to develop products to treat health problems including Alzheimer's disease, cancer, obesity, GI disorders, neurological and respiratory illnesses. BioAdvance was established with $33 million from the Commonwealth of Pennsylvania's share of tobacco settlement monies.
Halo Labs (formerly Optofluidics) is a venture-backed scientific instrumentation company that commercializes high throughput biopharmaceutical quality control tools using the latest optics, image processing, and microfluidics. Its investors and development partners include BioAdvance, the National Science Foundation, the Defense Advanced Research Projects Agency, and the Ben Franklin Technology Partners. In 2012 Optofluidics was named Philadelphia Life Sciences startup of the year. The company was founded in 2011 and headquartered in Pennsylvania, United States.
KayoThera is a biotechnology company developing therapeutics used to cure late-stage and metastatic cancers. Its programs work on inhibiting a key enzyme that is responsible for protecting the cancer cells and depleting regulatory T-cells that intends to cure hitherto incurable cancers and give hope to patients. The company's mission is to develop the first-in-class immuno- and targeted therapies to drive cures in advanced cancers KayoThera was founded in 2019 and is headquartered in Princeton, New Jersey.
Wellsheet organizes clinical information with machine learning to predict and visualize the most relevant information for patient care in a physician-friendly format within the existing EHR (Electronic Health Record). By allowing providers to arrive at clinical insights faster, Wellsheet improves early intervention and hospital efficiency, with proven impact in a 10,000 physician health system in NJ. Wellsheet has partnered with major EHR vendors including Epic and Cerner to distribute the Wellsheet product through a SaaS-based model for health system customers.
Palvella Therapeutics is a start-up life sciences company that focuses on relentlessly and selflessly serving abandoned patient populations with therapies. The company specializes in developing therapies that specifically target the root cause of the disease. Palvella Therapeutics was founded in 2015 and headquartered in Wayne, Pennsylvania.
Halo Labs (formerly Optofluidics) is a venture-backed scientific instrumentation company that commercializes high throughput biopharmaceutical quality control tools using the latest optics, image processing, and microfluidics. Its investors and development partners include BioAdvance, the National Science Foundation, the Defense Advanced Research Projects Agency, and the Ben Franklin Technology Partners. In 2012 Optofluidics was named Philadelphia Life Sciences startup of the year. The company was founded in 2011 and headquartered in Pennsylvania, United States.
Ride Health partners with healthcare organizations and transportation providers to manage transportation benefits, strengthen enterprise transportation programs, and improve access to care and social services for at-risk populations. We blend technology and data with a human approach to break down access barriers and solve some of the biggest transportation challenges that payers, providers, and life science organizations face. Our platform maps out each patient’s unique needs and preferences for the best ride experience across clinical and social needs, ensuring greater access, improved efficiencies, lower costs, and better outcomes.
Renovacor is a preclinical‑stage biopharmaceutical company focused on developing transformative gene therapy‑based treatments for cardiovascular disease. Renovacor’s lead program is a recombinant adeno-associated virus (AAV)‑based gene therapy for patients suffering from dilated cardiomyopathy (DCM) due to mutations in the Bcl2‑associated athanogene 3 (BAG3) gene. Dilated cardiomyopathy is a condition affecting over 3 million patients in the US and growing steadily. Many patients develop DCM due to ischemic heart disease. Recently subpopulations have been identified that develop DCM due to mutations in specific genes that have been shown to result in the development of DCM. One of these specific genes is the BAG3 gene. The prevalence of disease‑causing BAG3 haploinsufficiency is estimated at approximately 35,000 individuals in the United States, representing an orphan disease by FDA guidelines. It is estimated a similar number of DCM patients with BAG3 mutations exist in Europe. These patients are typically younger and progress to end-stage heart failure sooner than patients with ischemic heart disease. Currently, DCM patients with a BAG3 mutation are treated with standard of care for heart failure. Despite improvements in pharmacotherapy and care, the five‑year survival of a patient with DCM is only 50%. The development of a BAG3 gene replacement therapy for patients with DCM that carry BAG3 mutations could potentially prevent the progression of disease in this otherwise healthy population of young adults.
Pillo Health provides HIPAA compliant tools for caregivers and health organizations to deliver better care to loved ones and patients living at home. The company's care delivery platform is centered on an intelligent healthcare assistant called Pillo. In addition to managing medications, Pillo can provide patients at home with health and wellness information, can proactively deliver digital care plans into the home, and can connect the home to care teams via smart notifications and video calling. The company also offers an SDK for partner organizations to create their own unique skills for Pillo by leveraging the company's proprietary in home voice first device.
Halo Labs (formerly Optofluidics) is a venture-backed scientific instrumentation company that commercializes high throughput biopharmaceutical quality control tools using the latest optics, image processing, and microfluidics. Its investors and development partners include BioAdvance, the National Science Foundation, the Defense Advanced Research Projects Agency, and the Ben Franklin Technology Partners. In 2012 Optofluidics was named Philadelphia Life Sciences startup of the year. The company was founded in 2011 and headquartered in Pennsylvania, United States.
ENB Therapeutics is developing therapies to break drug resistance that occurs in over 50% of cancer patients. Its lead product, ENB-001, is a first-in-class, selective small molecule endothelin B receptor (ETBR) inhibitor shown in multiple preclinical studies to significantly reduce tumor growth and prolong survival in cancer animal models. ENB-001 is the key to unlock the full therapeutic potential of immunotherapy by restoring the ability of T-cells to infiltrate tumors, inhibiting metastasis, and prolonging patient survival. Granted Orphan Drug Designation by FDA in 2016, ENB-001 has solid market exclusivity and strong IP. A low cost, time-efficient development program provides near-term POC within 18 months from financing. A companion diagnostic will detect ETBR pathway over-expressers creating additional opportunities for indication expansion into multiple tumor types and broader participation in the multi-billion-dollar immunotherapy market. Its products, as combination therapy with immuno-oncology agents, create a new and superior standard of care that blocks key mechanisms of drug resistance, stimulates the immune system to fight cancer, and prevents cancer from spreading. ENB Therapeutics was founded in 2015 and is headquartered in New York, New York.
Bainbridge Health provides hospital systems with a clinical intelligence and data analytics platform to improve medication safety. It provides hospital safety professionals with an infusion pump management software solution to better manage pump data and enhance patient safety. Bainbridge Health also offers a clinician-focused infusion pump management system known as InfusionWare that enables clinicians to manage infusion data in one centralized location.
A biotech company, engages in developing monoclonal antibodies to treat fibrotic and remodeling diseases. The company was founded in 2012 and is headquartered in Bryn Mawr, Pennsylvania .
Oncora Medical is a digital health company integrating big data and machine learning into radiation oncology. Founded in 2014, Oncora's intuitive software platform allows for better collection and application of real world data for all healthcare related decisions, for the benefit of the patient.
Wellsheet organizes clinical information with machine learning to predict and visualize the most relevant information for patient care in a physician-friendly format within the existing EHR (Electronic Health Record). By allowing providers to arrive at clinical insights faster, Wellsheet improves early intervention and hospital efficiency, with proven impact in a 10,000 physician health system in NJ. Wellsheet has partnered with major EHR vendors including Epic and Cerner to distribute the Wellsheet product through a SaaS-based model for health system customers.
Genome Profiling, LLC (www.genprollc.com) is at the forefront of this rapidly emerging market with the first epigenetic biomarker discovery platform that combines a proprietary pre-NGS gDNA preparation kit matched to powerful NGS data analytics algorithms that plug-n-play into standard NGS workflows and enable one NGS run to deliver data for both genomic variant call analyses data AND epigenetic data.
WellTrackONE is a population health management company that offers an end-to-end solution to physician offices, ACOs, integrated delivery networks, hospitals, and other physician networks that helps them administer the Medicare Annual Wellness Visit to all their Medicare patients. The company provides clinical risk management services used to offer a comprehensive baseline report for detailing modifiable risk factors, preventative goals, and measurable data. It was founded in 2012 and headquartered in Hilton Head Island, South Carolina.
Palvella Therapeutics is a start-up life sciences company that focuses on relentlessly and selflessly serving abandoned patient populations with therapies. The company specializes in developing therapies that specifically target the root cause of the disease. Palvella Therapeutics was founded in 2015 and headquartered in Wayne, Pennsylvania.
CytoVas is a life science company with a unique cell-based informatics platform, CLOUD CYTOMICS™, that is advancing precision medicine by providing clinicians and drug developers with actionable information on novel cellular markers of disease progression and individual treatment response. The company’s technology uniquely enables it to mine flow cytometry data to rapidly identify and automate interpretation of novel cellular biomarkers. This breakthrough approach enables clients to make critical decisions in their efforts to develop and deliver safer, more precisely targeted therapies for patients. CLOUD CYTOMICS™ is broadly applicable across therapeutic areas and disease states and used throughout all stages of drug development. CytoVas is currently working with partners to exploit the technology’s potential in Cardiovascular Disease, Type 2 Diabetes, Preeclampsia, Alzheimer’s, Acute Myeloid Leukemia, Psoriasis, Rheumatoid Arthritis, and Peripheral Arterial Disease. Future studies are planned in Traumatic Brain Injury. Founded by world-renowned experts in computational biology, flow cytometry and cardiology at the University of Pennsylvania, the Company is led today by an experienced management team and scientific advisory board with a track record of success. Privately held, CytoVas is well funded by primary investments from the American Heart Association, the National Institutes of Health and the University of Pennsylvania, and a partnership with Becton Dickinson Biosciences, a world leader in flow cytometry.
HueDx is a Rapid, Quantitative, Assay-based (RQA) test development and launch platform that eliminates the need to develop physical devices and software to launch an RQA product.
TalexMedical is the proud producer of Infantear – a revolutionary Class I medical device for the treatment of external ear deformities in newborns. InfantEar is a simple, yet elegant, nonsurgical ear molding system, applied in the outpatient setting, replacing the costly, labor intensive surgical ear procedure. The unique, fully customizable device is made of soft materials for increased comfort. Targeted primarily to pediatricians, who can recognize and treat the ear anomaly with one two-week treatment applied to a patient in the first three weeks of life, avoiding the delayed and costly external referral with specialists. This helps us to achieve the Triple Aim of Healthcare – improved results, increased patient satisfaction and decreased cost.
Venatorx Pharmaceuticals is a private company that focuses on the discovery and development of novel anti-infectives to treat multi-drug-resistant (MDR) bacterial infections and hard-to-treat viral infections. The company was founded in 2010 and is headquartered in Malvern, Pennsylvania.
Ride Health partners with healthcare organizations and transportation providers to manage transportation benefits, strengthen enterprise transportation programs, and improve access to care and social services for at-risk populations. We blend technology and data with a human approach to break down access barriers and solve some of the biggest transportation challenges that payers, providers, and life science organizations face. Our platform maps out each patient’s unique needs and preferences for the best ride experience across clinical and social needs, ensuring greater access, improved efficiencies, lower costs, and better outcomes.
Pillo Health provides HIPAA compliant tools for caregivers and health organizations to deliver better care to loved ones and patients living at home. The company's care delivery platform is centered on an intelligent healthcare assistant called Pillo. In addition to managing medications, Pillo can provide patients at home with health and wellness information, can proactively deliver digital care plans into the home, and can connect the home to care teams via smart notifications and video calling. The company also offers an SDK for partner organizations to create their own unique skills for Pillo by leveraging the company's proprietary in home voice first device.
Keriton is an inpatient feeding management platform that ensures patient safety, improves nursing workflows, and delivers actionable analytics. The platform has managed over 1.5M feeds and prevented nearly 30,000 errors. The platform is proven to improve outcomes and reduce nursing time. The SaaS based platform has is deployed in many larger enterprise health systems.
Mebias Discovery holds a game-changing platform to discover next generation GPCR drugs devoid of on-target side effects once thought to be unavoidable.
Cohero Health offers a proprietary connected health platform for those with respiratory illness. Its sensor-based technology and engaging platform improve medication adherence and care coordination between patients and their care providers. The company offers a suite of tools and technology comprises form flexible inhaler sensors, mobile spirometers, to track real-time adherence and lung function, and a mobile application accessible on iPhone, iWatch, and Android. Cohero Health was founded in 2013 and is headquartered in New York.
Genome Profiling, LLC (www.genprollc.com) is at the forefront of this rapidly emerging market with the first epigenetic biomarker discovery platform that combines a proprietary pre-NGS gDNA preparation kit matched to powerful NGS data analytics algorithms that plug-n-play into standard NGS workflows and enable one NGS run to deliver data for both genomic variant call analyses data AND epigenetic data.
Immunome is a biotechnology company that specializes in immunotherapy, biotechnology, and antigen discovery. It features a software platform that enables the simultaneous discovery of novel antigens and the patient-derived, native antibodies that target those antigens.
Mebias Discovery holds a game-changing platform to discover next generation GPCR drugs devoid of on-target side effects once thought to be unavoidable.
Jenrin Discovery, is a pharmaceutical company, focuses on developing therapeutics for a variety of chronic diseases. It develops therapeutics for various diseases, including obesity, diabetes, and autoimmune/inflammatory disorders.
Bainbridge Health provides hospital systems with a clinical intelligence and data analytics platform to improve medication safety. It provides hospital safety professionals with an infusion pump management software solution to better manage pump data and enhance patient safety. Bainbridge Health also offers a clinician-focused infusion pump management system known as InfusionWare that enables clinicians to manage infusion data in one centralized location.
Enzium is dedicated to developing fluorescent based reagents for highly selective protease activity detection using their proprietary modular protein and dye technology. Their technology allows us to quickly swap out protein modules, much like legos, to easily build new, selective assay reagents. It is their goal to enable their customers to integrate the same reagent kit/assay in applications across entire research, drug, and diagnostic development pipelines.
Penn State Health Milton S. Hershey Medical Center is a 551-bed Level I regional trauma center. As Central Pennsylvania’s only academic medical center and home to the Children’s Hospital at Penn State Health Milton S. Hershey Medical Center and Penn State College of Medicine, we are looked to as a resource for the most complex adult and pediatric cases. We have earned ANCC Magnet Recognition, which confirms our commitment to provide a professional environment that supports staff development and quality patient care.
Cohero Health offers a proprietary connected health platform for those with respiratory illness. Its sensor-based technology and engaging platform improve medication adherence and care coordination between patients and their care providers. The company offers a suite of tools and technology comprises form flexible inhaler sensors, mobile spirometers, to track real-time adherence and lung function, and a mobile application accessible on iPhone, iWatch, and Android. Cohero Health was founded in 2013 and is headquartered in New York.
NobleMD develops point of care technology to learn about patients’ symptoms, behaviors and intentions while engaging them in actions they can take for their health
Jenrin Discovery, is a pharmaceutical company, focuses on developing therapeutics for a variety of chronic diseases. It develops therapeutics for various diseases, including obesity, diabetes, and autoimmune/inflammatory disorders.
Oncora Medical is a digital health company integrating big data and machine learning into radiation oncology. Founded in 2014, Oncora's intuitive software platform allows for better collection and application of real world data for all healthcare related decisions, for the benefit of the patient.
Mebias Discovery holds a game-changing platform to discover next generation GPCR drugs devoid of on-target side effects once thought to be unavoidable.
Enzium is dedicated to developing fluorescent based reagents for highly selective protease activity detection using their proprietary modular protein and dye technology. Their technology allows us to quickly swap out protein modules, much like legos, to easily build new, selective assay reagents. It is their goal to enable their customers to integrate the same reagent kit/assay in applications across entire research, drug, and diagnostic development pipelines.
RiboNova is a biopharmaceutical company in the Lankenau Institute for Medical Research near Philadelphia. The company is developing novel therapies for the treatment of serious rare diseases, including mitochondrial disease and certain cancers. RiboNova's drug discovery platform is targeting transfer RNA molecules.
Cohero Health offers a proprietary connected health platform for those with respiratory illness. Its sensor-based technology and engaging platform improve medication adherence and care coordination between patients and their care providers. The company offers a suite of tools and technology comprises form flexible inhaler sensors, mobile spirometers, to track real-time adherence and lung function, and a mobile application accessible on iPhone, iWatch, and Android. Cohero Health was founded in 2013 and is headquartered in New York.
Hsiri Therapeutics is a development stage pharmaceutical company engaged in the discovery and development of new antibiotics to treat diseases caused by drug resistant bacteria. Hsiri Therapeutics’ efforts are primarily directed at two discrete groups of pathogens – mycobacterial diseases and gram-negative infections. Hsiri Therapetics was formed based on the antibiotic research that originated in the laboratories of Professor Marvin Miller at the University of Notre Dame.
Enzium is dedicated to developing fluorescent based reagents for highly selective protease activity detection using their proprietary modular protein and dye technology. Their technology allows us to quickly swap out protein modules, much like legos, to easily build new, selective assay reagents. It is their goal to enable their customers to integrate the same reagent kit/assay in applications across entire research, drug, and diagnostic development pipelines.
CarePartners Plus LLC, a healthcare data and information company, provides patient management solutions. It offers Wellby, a patient engagement technology system that helps people in following steps for better health. The company also provides patient engagement, caregiver management, care coordination, and cost containment solutions for hospitals and physician groups. It serves patients and consumers; employers and associations; government agencies; health insurers; hospital and medical groups; public health system centers; accreditation organizations; health care professionals; educators and researchers; and investors. CarePartners Plus LLC was incorporated in 2009 and is based in Horsham .
Allevi offers bioprinters that enable users to experiment with any biomaterial, work with any cell line, and print in any geometry. Its platform empowers novice and expert 3D bioprinting users alike to quickly and easily achieve their goals.
WellTrackONE is a population health management company that offers an end-to-end solution to physician offices, ACOs, integrated delivery networks, hospitals, and other physician networks that helps them administer the Medicare Annual Wellness Visit to all their Medicare patients. The company provides clinical risk management services used to offer a comprehensive baseline report for detailing modifiable risk factors, preventative goals, and measurable data. It was founded in 2012 and headquartered in Hilton Head Island, South Carolina.
Galleon Pharmaceuticals engages in the discovery and development of medicines for breathing-control conditions in the United States. It focuses on developing a portfolio of therapeutics for the treatment of sleep apnea, ventilator weaning, anesthetic/analgesic-induced respiratory depression, COPD, obesity-hypoventilation syndrome, and other common diseases. The company was incorporated in 2003 and is based in Horsham, Pennsylvania.
Enzium is dedicated to developing fluorescent based reagents for highly selective protease activity detection using their proprietary modular protein and dye technology. Their technology allows us to quickly swap out protein modules, much like legos, to easily build new, selective assay reagents. It is their goal to enable their customers to integrate the same reagent kit/assay in applications across entire research, drug, and diagnostic development pipelines.
HealthQX specializes in Value-based Payment (VBP) analytic software solutions for health plans and providers. Its VBP analytics platform, ClarityQx, provides the capabilities to design, implement, and monitor the on-going performance of payment models such as episodic, bundled, or accountable care arrangements. The company was founded in 2012 and is based in King Of Prussia, Pennsylvania.
TowerView helps the 1 in 3 Americans with a chronic illness manage multiple medications. TowerView’s patients receive pre-filled medication trays that fit into a connected pillbox like a K-Cup into a Keurig coffee machine. Their pillbox can sense when patients forget a dose and automatically sends a text or phone reminder. Unlike other smart pillboxes, they send patients pre-filled medication trays sourced from a pharmacy so patients never have to fill their own pillbox and they work directly with nurses to target outreach for non-adherent patients. TowerView is rolling out with Independence Blue Cross in January 2015 and are in advanced discussions with numerous other health plans.
Jenrin Discovery, is a pharmaceutical company, focuses on developing therapeutics for a variety of chronic diseases. It develops therapeutics for various diseases, including obesity, diabetes, and autoimmune/inflammatory disorders.
Merganser Biotech is a research company that is engaged in the development and licensing of medicines for the treatment of hematological and iron overload diseases that include beta thalassemia and hemochromatosis. The company develops hepcidin mimetic peptides to control iron metabolism and ineffective erythropoiesis. the company was founded 2011 and is based in Newtown Square, Pennsylvania.
Hsiri Therapeutics is a development stage pharmaceutical company engaged in the discovery and development of new antibiotics to treat diseases caused by drug resistant bacteria. Hsiri Therapeutics’ efforts are primarily directed at two discrete groups of pathogens – mycobacterial diseases and gram-negative infections. Hsiri Therapetics was formed based on the antibiotic research that originated in the laboratories of Professor Marvin Miller at the University of Notre Dame.
Novira Therapeutics is an antiviral drug discovery company that is focused on the discovery of first-in-class antiviral therapeutics for the treatment of chronic HBV and HIV infections, two global diseases with high levels of unmet need. Novira’s oral drugs target the capsid of the virus, and offer a promising treatment option both as monotherapy and in combination with current standards of care. The company’s antivirals potentially address limitations in treating chronic HBV infection, a disease for which the only class of oral drugs available, polymerase inhibitors, are rarely curative and often require lifelong treatment, as well as in chronic HIV infection, a disease for which the continued ability of the virus to mutate inevitably leads to drug-resistant viral strains. Each of these limitations to the standard of care can potentially be addressed by capsid inhibitors which feature a new mechanism of action.
OSSIANIX is a privately held biotherapeutics company that develops single domain antibodies based on the highly versatile VNAR structure from shark. Due to remarkable biological and biophysical properties, the VNAR platform can rapidly deliver unique, exquisitely high-affinity products to multiple target classes and overcomes most disadvantages of conventional monoclonal antibody therapy. The platform is also ideal for generating bispecific and trispecific products that can be engineered with ease to develop products with differentiated features in clinically meaningful conditions and also allow targeting to both the blood brain barrier and GI tract for CNS and oral applications.
Immunome is a biotechnology company that specializes in immunotherapy, biotechnology, and antigen discovery. It features a software platform that enables the simultaneous discovery of novel antigens and the patient-derived, native antibodies that target those antigens.
Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Our experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada' s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 has entered late-stage development as an adjunctive treatment for MDD in adults.()
Jenrin Discovery, is a pharmaceutical company, focuses on developing therapeutics for a variety of chronic diseases. It develops therapeutics for various diseases, including obesity, diabetes, and autoimmune/inflammatory disorders.
Halo Labs (formerly Optofluidics) is a venture-backed scientific instrumentation company that commercializes high throughput biopharmaceutical quality control tools using the latest optics, image processing, and microfluidics. Its investors and development partners include BioAdvance, the National Science Foundation, the Defense Advanced Research Projects Agency, and the Ben Franklin Technology Partners. In 2012 Optofluidics was named Philadelphia Life Sciences startup of the year. The company was founded in 2011 and headquartered in Pennsylvania, United States.
Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Our experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada' s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 has entered late-stage development as an adjunctive treatment for MDD in adults.()
BioDetego is developing, VASPfore, a new biomarker test for selecting cancer treatment protocols. The VASP marker provides information that will direct chemotherapy to high risk patients who will likely benefit from treatment while preventing costly and harmful treatment of low risk patients. BioDetego predicts that the VASPfore will provide payors enormous savings (>$150MM/year) by reducing total treatment costs. The company is led by David Zuzga, Ph.D., Founder and CEO, a research scientist with expertise in cell and molecular biology at La Salle University & Giovanni M. Pitari, M.D., Ph.D. Founder and CSO, a physician and research scientist with expertise in Translational Oncology.
HealthQX specializes in Value-based Payment (VBP) analytic software solutions for health plans and providers. Its VBP analytics platform, ClarityQx, provides the capabilities to design, implement, and monitor the on-going performance of payment models such as episodic, bundled, or accountable care arrangements. The company was founded in 2012 and is based in King Of Prussia, Pennsylvania.
InfraScan is a medical device company that invented and distributes hand-held diagnostic devices for head injury and stroke assessment based on Near-Infrared (NIR) technology. The Infrascanner enables clinicians to effectively, conveniently, and accurately detect intracranial bleeding in patients with head trauma. Intracranial hematomas are an important and, if diagnosed early, treatable cause of secondary brain injury in patients with head trauma. Recent statistics from Iraq shows that 30% of all wounded in action have head injuries, and 40% of them have brain hematomas. Dr. Britton Chance (University of Pennsylvania) and Dr. Claudia Robertson (Baylor College of Medicine) invented a NIR system for detection of brain hematomas and tested it successfully in 305 patients in Baylor. An entrepreneurial team formed a company around this technology in collaboration with Drexel University and won the Wharton Business Plan competition in April 2004 and the second prize at the global business plan competition in Singapore in October 2004. The Office of Naval Research funded the company in May, the Biotechnology Greenhouse of Southeastern Pennsylvania, from Ben Franklin Technology Partners of Southeastern Pennsylvania, and from Philadelphia Industrial Development Corporation. A multi-center clinical study to support an FDA submission started in July 2006, and on February 2008 an application was submitted to the FDA.
Merganser Biotech is a research company that is engaged in the development and licensing of medicines for the treatment of hematological and iron overload diseases that include beta thalassemia and hemochromatosis. The company develops hepcidin mimetic peptides to control iron metabolism and ineffective erythropoiesis. the company was founded 2011 and is based in Newtown Square, Pennsylvania.
Venatorx Pharmaceuticals is a private company that focuses on the discovery and development of novel anti-infectives to treat multi-drug-resistant (MDR) bacterial infections and hard-to-treat viral infections. The company was founded in 2010 and is headquartered in Malvern, Pennsylvania.
Immunome is a biotechnology company that specializes in immunotherapy, biotechnology, and antigen discovery. It features a software platform that enables the simultaneous discovery of novel antigens and the patient-derived, native antibodies that target those antigens.
Halo Labs (formerly Optofluidics) is a venture-backed scientific instrumentation company that commercializes high throughput biopharmaceutical quality control tools using the latest optics, image processing, and microfluidics. Its investors and development partners include BioAdvance, the National Science Foundation, the Defense Advanced Research Projects Agency, and the Ben Franklin Technology Partners. In 2012 Optofluidics was named Philadelphia Life Sciences startup of the year. The company was founded in 2011 and headquartered in Pennsylvania, United States.
Microbiota
Seed Round in 2013
Microbiota is spun out from university of Pennsylvania, to develop a gut microbiome-based treatment for hyperammonemia.
Annovis Bio is specialty pharmaceutical company founded to develop novel treatments for Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative disorders. The company has two compounds in clinical development: Posiphen® targets early stage AD and PD and may stop or slow the progression of the disease; BNC targets late stage AD and may stabilize the decline.
OSSIANIX is a privately held biotherapeutics company that develops single domain antibodies based on the highly versatile VNAR structure from shark. Due to remarkable biological and biophysical properties, the VNAR platform can rapidly deliver unique, exquisitely high-affinity products to multiple target classes and overcomes most disadvantages of conventional monoclonal antibody therapy. The platform is also ideal for generating bispecific and trispecific products that can be engineered with ease to develop products with differentiated features in clinically meaningful conditions and also allow targeting to both the blood brain barrier and GI tract for CNS and oral applications.
Enzium is dedicated to developing fluorescent based reagents for highly selective protease activity detection using their proprietary modular protein and dye technology. Their technology allows us to quickly swap out protein modules, much like legos, to easily build new, selective assay reagents. It is their goal to enable their customers to integrate the same reagent kit/assay in applications across entire research, drug, and diagnostic development pipelines.
Merganser Biotech is a research company that is engaged in the development and licensing of medicines for the treatment of hematological and iron overload diseases that include beta thalassemia and hemochromatosis. The company develops hepcidin mimetic peptides to control iron metabolism and ineffective erythropoiesis. the company was founded 2011 and is based in Newtown Square, Pennsylvania.
Novira Therapeutics is an antiviral drug discovery company that is focused on the discovery of first-in-class antiviral therapeutics for the treatment of chronic HBV and HIV infections, two global diseases with high levels of unmet need. Novira’s oral drugs target the capsid of the virus, and offer a promising treatment option both as monotherapy and in combination with current standards of care. The company’s antivirals potentially address limitations in treating chronic HBV infection, a disease for which the only class of oral drugs available, polymerase inhibitors, are rarely curative and often require lifelong treatment, as well as in chronic HIV infection, a disease for which the continued ability of the virus to mutate inevitably leads to drug-resistant viral strains. Each of these limitations to the standard of care can potentially be addressed by capsid inhibitors which feature a new mechanism of action.
Immunome is a biotechnology company that specializes in immunotherapy, biotechnology, and antigen discovery. It features a software platform that enables the simultaneous discovery of novel antigens and the patient-derived, native antibodies that target those antigens.
Jenrin Discovery, is a pharmaceutical company, focuses on developing therapeutics for a variety of chronic diseases. It develops therapeutics for various diseases, including obesity, diabetes, and autoimmune/inflammatory disorders.
Merganser Biotech is a research company that is engaged in the development and licensing of medicines for the treatment of hematological and iron overload diseases that include beta thalassemia and hemochromatosis. The company develops hepcidin mimetic peptides to control iron metabolism and ineffective erythropoiesis. the company was founded 2011 and is based in Newtown Square, Pennsylvania.
Niiki Pharma is a development focused oncology company specializing in first-in-class cancer treatments directed at novel cellular targets and related companion diagnostics. With a team of experts in cancer drug development and commercialization, Niiki Pharma programs are characterized by quality, speed and capital efficient processes.
Their technology has a proven track record since January 2010. ISS engages as a partner to aid their customers in managing their portfolios using their proprietary platform. They deliver unprecedented results with speed and efficiency enabling variances less than 10% from forecasts. Multiple deployment options customized for their customers.
Anakim
Seed Round in 2012
Anakim Biologics is developing efficiencies and improvements in biologics manufacturing.
TREVENTIS Corporation is dedicated to treating and preventing protein misfolding diseases. We utilize a proprietary, patent-pending discovery engine – Common Conformational Morphology (CCM) – to identify druggable active sites in misfolded protein targets. CCM combines unique in silico models with deep expertise in model development (in vitro, ex vivo, in vivo) to enable rational drug design against misfolded protein targets. Our lead program focuses on anti-misfolding small molecules in tauopathy (3R, 4R, familial mutations and mixed) with relevance to Alzheimer’s disease. We have further CCM-driven efforts in oncology and other neurodegenerative diseases that show the wide utility of our technology platform.
Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Our experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada' s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 has entered late-stage development as an adjunctive treatment for MDD in adults.()
Their technology has a proven track record since January 2010. ISS engages as a partner to aid their customers in managing their portfolios using their proprietary platform. They deliver unprecedented results with speed and efficiency enabling variances less than 10% from forecasts. Multiple deployment options customized for their customers.
Halo Labs (formerly Optofluidics) is a venture-backed scientific instrumentation company that commercializes high throughput biopharmaceutical quality control tools using the latest optics, image processing, and microfluidics. Its investors and development partners include BioAdvance, the National Science Foundation, the Defense Advanced Research Projects Agency, and the Ben Franklin Technology Partners. In 2012 Optofluidics was named Philadelphia Life Sciences startup of the year. The company was founded in 2011 and headquartered in Pennsylvania, United States.
Melior Discovery is dedicated to uncovering new therapeutic applications for partners' existing drugs. By utilizing the unique and highly efficient theraTRACEÂ indications discovery platform, Melior can systematically study a single compound in multiple in vivo models, thereby evaluating potential utility in a variety of major therapeutic areas.
Ceptaris Therapeutics, Inc. is a privately held, specialty pharmaceutical company that is developing a proprietary gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma (CTCL). If approved, Ceptaris' investigational drug would be the first topical mechlorethamine product available to treat the signs and symptoms of this rare cancer.
Imiplex develops engineered protein nanostructures for applications in targeted therapeutics, biosensors, and functional biomaterials. Imiplex's technology capitalizes on the unique properties of proteins, including their ability to self-assemble with atomic precision, their structural and functional diversity, ease of engineering using recombinant DNA technology, and scalable production economics.
COOL~BIO is a biotechnology company focused on developing hypothermia-activated biologics. Therapeutic hypothermia (TH) is the process of cooling the body to prevent organ damage and is widely-used in cardiac surgery, ischemic stroke, cardiac arrest, neurosurgery and traumatic brain injury. Their lead molecule is an anti-platelet agent being developed for use during cardiopulmonary bypass.
CarePartners Plus LLC, a healthcare data and information company, provides patient management solutions. It offers Wellby, a patient engagement technology system that helps people in following steps for better health. The company also provides patient engagement, caregiver management, care coordination, and cost containment solutions for hospitals and physician groups. It serves patients and consumers; employers and associations; government agencies; health insurers; hospital and medical groups; public health system centers; accreditation organizations; health care professionals; educators and researchers; and investors. CarePartners Plus LLC was incorporated in 2009 and is based in Horsham .
Galleon Pharmaceuticals engages in the discovery and development of medicines for breathing-control conditions in the United States. It focuses on developing a portfolio of therapeutics for the treatment of sleep apnea, ventilator weaning, anesthetic/analgesic-induced respiratory depression, COPD, obesity-hypoventilation syndrome, and other common diseases. The company was incorporated in 2003 and is based in Horsham, Pennsylvania.
RMH Sciences
Seed Round in 2012
RMH Sciences aims to commercialize newly discovered antibiotics by Dr. Harvey Rubin, University of Pennsylvania Professor of Medicine. One of RMH’s most promising ventures focuses on creating antibiotics to combat hospital acquired bacterial pathogens, a largely unmet need in the current marketplace.
Immunome is a biotechnology company that specializes in immunotherapy, biotechnology, and antigen discovery. It features a software platform that enables the simultaneous discovery of novel antigens and the patient-derived, native antibodies that target those antigens.
Melior Discovery is dedicated to uncovering new therapeutic applications for partners' existing drugs. By utilizing the unique and highly efficient theraTRACEÂ indications discovery platform, Melior can systematically study a single compound in multiple in vivo models, thereby evaluating potential utility in a variety of major therapeutic areas.
Niiki Pharma is a development focused oncology company specializing in first-in-class cancer treatments directed at novel cellular targets and related companion diagnostics. With a team of experts in cancer drug development and commercialization, Niiki Pharma programs are characterized by quality, speed and capital efficient processes.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.